WHO Prequalifies Bavarian Nordic's MVA-BN as First Mpox Vaccine for Emergency Use

Sep 13, 2024, 10:24 AM

The World Health Organization (WHO) has prequalified Bavarian Nordic's MVA-BN vaccine as the first vaccine against mpox. This approval marks a significant step towards expanding access and reducing transmission in high-risk communities, particularly in Africa where the disease has been prevalent. The MVA-BN vaccine, which is also indicated for smallpox, is now eligible for procurement by UN agencies, facilitating broader distribution to those in need. WHO Director-General Dr. Tedros Adhanom Ghebreyesus emphasized the importance of this development in the fight against mpox. The vaccine has been approved for emergency use in adults.